Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities

Chungsoo Kim, Mona Sharifi, Joseph S. Ross, Yong Chen, Hua Xu, Harlan M. Krumholz, Yuan LumedRxiv 2025 · DOI

TL;DR

While GLP-1 receptor agonists (GLP-1RAs) are transformative for treating adolescent obesity, this study of over 2 million patients reveals that fewer than 1% of eligible teens actually receive a prescription. Even as uptake accelerates, stark disparities persist: males, Black and Hispanic youth, rural residents, and those on Medicaid are significantly less likely to access these medications than their peers.

What Problem Does This Paper Address?

Obesity affects nearly one in five children and adolescents in the U.S., often leading to lifelong health complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs)—specifically semaglutide—have shown remarkable efficacy in clinical trials for this age group. However, clinical trial success doesn't always translate to equitable real-world access.

Previous research has looked at who is eligible for these drugs or who dispenses them at pharmacies, but there is a "black box" at the point of care: the prescribing decision. The authors sought to understand the national prescribing patterns among U.S. adolescents with obesity and identify whether demographic or socioeconomic factors create barriers to receiving these therapies.

Methods

The researchers conducted a retrospective cohort study using the Epic Cosmos dataset, a massive repository of de-identified electronic health record (EHR) data.

  • Study Period: January 1, 2021, to July 31, 2025.
  • Population: 2,090,467 adolescents (ages 12–17) with obesity (BMI $\ge$ 95th percentile).
  • Exclusions: Patients with Type 1 or Type 2 diabetes were excluded to ensure the focus remained on obesity treatment.
  • Analysis: The team tracked prescriptions for liraglutide, semaglutide, and tirzepatide (the latter included to capture off-label use). They used multivariable logistic regression to calculate adjusted odds ratios (aORs), controlling for factors like obesity class, insurance type, and neighborhood social vulnerability.

Datasets

The study utilized the Epic Cosmos dataset. This is a large-scale, national EHR dataset that aggregates data from hundreds of healthcare organizations across the U.S. Unlike smaller clinical datasets, Cosmos provides a high-resolution look at real-world clinical practice across diverse geographic and socioeconomic strata.

Key Insights and Ideas

  • The "Semaglutide Inflection Point": Prescribing rates were nearly flat until the FDA approved semaglutide for adolescents in December 2022. Following approval, the incident prescription rate jumped from 0.15% to 0.77% by mid-2025, with semaglutide rapidly becoming the dominant choice.
  • The Severity Threshold: Prescribing is heavily skewed toward the most severe cases. Adolescents with Class III obesity (the most severe) were 21 times more likely to receive a prescription than those with Class I obesity. This suggests clinicians currently view GLP-1RAs as a "rescue" therapy for extreme cases rather than a preventative tool for moderate obesity.
  • The Insurance Barrier: Even after adjusting for clinical severity, patients with Medicaid were 43% less likely to receive a prescription compared to those with commercial insurance. This highlights the massive impact of state-level coverage variations and prior authorization hurdles.
  • Demographic and Geographic Gaps: Disparities aren't just financial. Males, Hispanic/Latino youth, Black youth, and those living in rural or disadvantaged neighborhoods all faced significantly lower odds of receiving a prescription, suggesting a complex interplay of provider bias, patient preference, and structural access issues.

Key Results

  • Overall Uptake: Only 0.9% (19,097) of the 2 million eligible adolescents received at least one GLP-1RA prescription during the study period.
  • Prevalence Growth: The prevalent prescription rate grew from 0.12% to 1.38% between late 2022 and mid-2025.
  • Demographic Odds:
    • Males: aOR 0.53 (47% less likely than females).
  • Black Youth: aOR 0.89 (11% less likely than White youth).
  • Rural Residents: aOR 0.80 (20% less likely than metropolitan residents).
  • Socioeconomic Odds:
    • Medicaid: aOR 0.57.
  • Self-pay: aOR 0.20.
  • Disadvantaged Neighborhoods (SVI): aOR 0.61.

Limitations and Future Work

The authors acknowledge several key limitations:

  1. Prescribing vs. Dispensing: The study tracks prescriptions written, not whether the patient actually picked up the medication. High costs and insurance denials often prevent a prescription from being filled.
  2. Lack of Qualitative Context: The EHR data doesn't capture the "why" behind the disparities—whether they stem from provider hesitancy, patient/parental concerns, or administrative "red tape."
  3. Adherence: There is no data on how long patients stayed on the medication or their clinical outcomes (weight loss) following the script.

Future Work: Research is needed to investigate the specific impact of insurance prior-authorization requirements and to develop interventions that ensure these high-efficacy treatments reach the populations most burdened by obesity-related health inequities.

Summary updated

Abstract

This retrospective cohort study examined national prescribing patterns of glucagon like peptide 1 receptor agonists (GLP1RAs) for U.S. adolescents with obesity using electronic health record data from over 2 million patients aged 12 to 17 years between 2021 and 2025. Among eligible adolescents, only 0.9 received a GLP1RA prescription, though use increased after semaglutide approval in December 2022, with semaglutide rapidly surpassing liraglutide and off-label tirzepatide use rising by 2025. Prescribing was strongly associated with clinical and sociodemographic factors: adolescents with severe obesity were more likely to be prescribed, while males, Hispanic/Latino and non Hispanic Black youth, non English/Spanish speakers, those living in rural or socioeconomically disadvantaged areas, and those with Medicaid or self pay coverage were significantly less likely to receive prescriptions. These findings highlight growing uptake of GLP1RAs but reveal substantial disparities in access, suggesting insurance barriers and structural inequities may limit availability for groups disproportionately affected by obesity.
BibTeX
@misc{kim2025prescribing,
  author = {Chungsoo Kim and Mona Sharifi and Joseph S. Ross and Yong Chen and Hua Xu and Harlan M. Krumholz and Yuan Lu},
  title = {{Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities}},
  year = {2025},
  doi = {10.1101/2025.10.06.25337411},
  howpublished = {medRxiv},
}
Figure